Galashiels-based pharmaceutical company ProStrakan has announced a deal with a US firm which could be worth up to £80m over the next 15 years.
The deal with biotech giant Amgen is worth about £4.5m initially.
Under the agreement, the company gets exclusive rights to develop and commercialise ProStrakan's pre-clinical compounds for kidney disease.
The news comes after the Borders company recently revealed sales of £16m for the first six months of the year.
ProStrakan CEO Dr Wilson Totten said he was delighted to have entered into the US deal.
He added that the agreement recognised the "world class research" of the company's discovery unit.
~RS~q~RS~~RS~z~RS~29~RS~)
~RS~q~RS~~RS~z~RS~29~RS~)
One-Minute World News
News services
E-mail this to a friend
Printable version
